Tumor immunogenomic signatures improve a prognostic model of melanoma survival

BACKGROUND: Tumor mutation burden (TMB) has been associated with melanoma immunotherapy (IT) outcomes, including survival. We explored whether combining TMB with immunogenomic signatures recently identified by The Cancer Genome Atlas (TCGA) can refine melanoma prognostic models of overall survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Morales, Leah, Simpson, Danny, Ferguson, Robert, Cadley, John, Esteva, Eduardo, Monson, Kelsey, Chat, Vylyny, Martinez, Carlos, Weber, Jeffrey, Osman, Iman, Kirchhoff, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888085/
https://www.ncbi.nlm.nih.gov/pubmed/33596955
http://dx.doi.org/10.1186/s12967-021-02738-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888085/
https://www.ncbi.nlm.nih.gov/pubmed/33596955
http://dx.doi.org/10.1186/s12967-021-02738-0

Ejemplares similares